<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Spinal Muscular Atrophy - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Spinal Muscular Atrophy</span>
        </nav>

        <header class="page-header">
            <h1>Spinal Muscular Atrophy</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0001516" target="_blank">
                        MONDO:0001516
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Motor Neuron Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neuromuscular Disease</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Subtypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">SMA Type 1 (Werdnig-Hoffmann)</div>
                
                <div class="item-desc">Most severe, onset before 6 months, never sit independently, death usually by age 2.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">SMA Type 2</div>
                
                <div class="item-desc">Intermediate, onset 6-18 months, can sit but never walk independently.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">SMA Type 3 (Kugelberg-Welander)</div>
                
                <div class="item-desc">Milder, onset after 18 months, can walk but may lose ability later.</div>
                
                
    
    
            </div>
            
            <div class="item-box subtype-box">
                <div class="item-name">SMA Type 4</div>
                
                <div class="item-desc">Adult onset, mildest form, normal lifespan with mild weakness.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">SMN Protein Deficiency</div>
                
                <div class="item-desc">Homozygous deletion or mutation of SMN1 gene causes deficiency of survival motor neuron protein. SMN2 gene produces some functional protein but mostly truncated due to exon 7 skipping. SMN protein is essential for motor neuron survival and function.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Motor Neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Motor Neuron Development</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16364894" target="_blank">PMID:16364894</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"SMA is caused by mutations in a single gene, the Survival of Motor Neuron 1 (SMN1) gene."</div>
                
                
                <div class="evidence-explanation">Review confirms SMN1 gene mutations cause SMA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18572081" target="_blank">PMID:18572081</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion,..."</div>
                
                
                <div class="evidence-explanation">Lancet review confirms SMN1 gene disruption causes SMA with motor neuron degeneration.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Motor Neuron Degeneration</div>
                
                <div class="item-desc">Loss of alpha motor neurons in the anterior horn of the spinal cord leads to progressive denervation of skeletal muscles. Proximal muscles are more severely affected than distal muscles.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Motor Neuron
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000100" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Neurodegeneration</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16364894" target="_blank">PMID:16364894</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease results in motor neuron loss and skeletal muscle atrophy."</div>
                
                
                <div class="evidence-explanation">Review confirms motor neuron loss as the pathological basis of SMA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hypotonia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001252" target="_blank">
                            HP:0001252
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Floppy infant presentation in severe forms</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18572081" target="_blank">PMID:18572081</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."</div>
                
                
                <div class="evidence-explanation">Lancet review confirms generalized weakness as a characteristic of SMA, presenting as hypotonia in infants.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Progressive Muscle Weakness
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003323" target="_blank">
                            HP:0003323
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Symmetric, proximal greater than distal</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16364894" target="_blank">PMID:16364894</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease results in motor neuron loss and skeletal muscle atrophy."</div>
                
                
                <div class="evidence-explanation">Review confirms skeletal muscle atrophy (weakness) as a direct result of motor neuron loss in SMA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Areflexia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001284" target="_blank">
                            HP:0001284
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Absent deep tendon reflexes</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18572081" target="_blank">PMID:18572081</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness."</div>
                
                
                <div class="evidence-explanation">Motor neuron degeneration leads to loss of deep tendon reflexes (areflexia).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fasciculations
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002380" target="_blank">
                            HP:0002380
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Tongue fasciculations particularly characteristic</div>
                
                
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Respiratory Failure
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002878" target="_blank">
                            HP:0002878
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Leading cause of death in SMA types 1 and 2</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29091570" target="_blank">PMID:29091570</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005)."</div>
                
                
                <div class="evidence-explanation">ENDEAR trial uses permanent assisted ventilation as a primary endpoint, confirming respiratory failure as a key clinical outcome in infantile SMA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Scoliosis
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002650" target="_blank">
                            HP:0002650
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive spinal curvature due to paraspinal muscle weakness</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16364894" target="_blank">PMID:16364894</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease results in motor neuron loss and skeletal muscle atrophy."</div>
                
                
                <div class="evidence-explanation">Progressive muscle weakness including paraspinal muscles leads to scoliosis in SMA patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SMN1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18572081" target="_blank">PMID:18572081</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation."</div>
                
                
                <div class="evidence-explanation">Lancet review confirms SMN1 gene disruption is the causative mechanism of SMA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SMN2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Modifier)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nusinersen (Spinraza)
                    
                </div>
                
                <div class="item-desc">Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29091570" target="_blank">PMID:29091570</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group."</div>
                
                
                <div class="evidence-explanation">ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29091570" target="_blank">PMID:29091570</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein."</div>
                
                
                <div class="evidence-explanation">NEJM paper confirms mechanism of action of nusinersen.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Onasemnogene abeparvovec (Zolgensma)
                    
                </div>
                
                <div class="item-desc">AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35715567" target="_blank">PMID:35715567</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention."</div>
                
                
                <div class="evidence-explanation">SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Risdiplam (Evrysdi)
                    
                </div>
                
                <div class="item-desc">Oral small molecule SMN2 splicing modifier, daily oral administration.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34320287" target="_blank">PMID:34320287</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts."</div>
                
                
                <div class="evidence-explanation">FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                </div>
                
                <div class="item-desc">Respiratory support, nutritional management, physical therapy, orthopedic interventions.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatine Kinase
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Normal or mildly elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Unlike muscular dystrophies, CK is typically normal or only mildly elevated</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Spinal Muscular Atrophy
category: Genetic
parents:
- Motor Neuron Disease
- Neuromuscular Disease
disease_term:
  preferred_term: spinal muscular atrophy
  term:
    id: MONDO:0001516
    label: spinal muscular atrophy
has_subtypes:
- name: SMA Type 1 (Werdnig-Hoffmann)
  description: Most severe, onset before 6 months, never sit independently, death usually by age 2.
- name: SMA Type 2
  description: Intermediate, onset 6-18 months, can sit but never walk independently.
- name: SMA Type 3 (Kugelberg-Welander)
  description: Milder, onset after 18 months, can walk but may lose ability later.
- name: SMA Type 4
  description: Adult onset, mildest form, normal lifespan with mild weakness.
pathophysiology:
- name: SMN Protein Deficiency
  description: &gt;
    Homozygous deletion or mutation of SMN1 gene causes deficiency of survival motor neuron protein.
    SMN2 gene produces some functional protein but mostly truncated due to exon 7 skipping.
    SMN protein is essential for motor neuron survival and function.
  cell_types:
  - preferred_term: Motor Neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: Motor Neuron Development
    term:
      id: GO:0048666
      label: neuron development
  evidence:
  - reference: PMID:16364894
    supports: SUPPORT
    snippet: &#34;SMA is caused by mutations in a single gene, the Survival of Motor Neuron 1 (SMN1) gene.&#34;
    explanation: Review confirms SMN1 gene mutations cause SMA.
  - reference: PMID:18572081
    supports: SUPPORT
    snippet: &#34;Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness. It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation.&#34;
    explanation: Lancet review confirms SMN1 gene disruption causes SMA with motor neuron degeneration.
- name: Motor Neuron Degeneration
  description: &gt;
    Loss of alpha motor neurons in the anterior horn of the spinal cord leads to
    progressive denervation of skeletal muscles. Proximal muscles are more severely
    affected than distal muscles.
  cell_types:
  - preferred_term: Motor Neuron
    term:
      id: CL:0000100
      label: motor neuron
  biological_processes:
  - preferred_term: Neurodegeneration
    term:
      id: GO:0070997
      label: neuron death
  evidence:
  - reference: PMID:16364894
    supports: SUPPORT
    snippet: &#34;The disease results in motor neuron loss and skeletal muscle atrophy.&#34;
    explanation: Review confirms motor neuron loss as the pathological basis of SMA.
phenotypes:
- name: Hypotonia
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Floppy infant presentation in severe forms
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:18572081
    supports: SUPPORT
    snippet: &#34;Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness.&#34;
    explanation: Lancet review confirms generalized weakness as a characteristic of SMA, presenting as hypotonia in infants.
- name: Progressive Muscle Weakness
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Symmetric, proximal greater than distal
  phenotype_term:
    preferred_term: Progressive Muscle Weakness
    term:
      id: HP:0003323
      label: Progressive muscle weakness
  evidence:
  - reference: PMID:16364894
    supports: SUPPORT
    snippet: &#34;The disease results in motor neuron loss and skeletal muscle atrophy.&#34;
    explanation: Review confirms skeletal muscle atrophy (weakness) as a direct result of motor neuron loss in SMA.
- name: Areflexia
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Absent deep tendon reflexes
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:18572081
    supports: SUPPORT
    snippet: &#34;Spinal muscular atrophy is an autosomal recessive neurodegenerative disease characterised by degeneration of spinal cord motor neurons, atrophy of skeletal muscles, and generalised weakness.&#34;
    explanation: Motor neuron degeneration leads to loss of deep tendon reflexes (areflexia).
- name: Fasciculations
  category: Neurological
  frequency: FREQUENT
  notes: Tongue fasciculations particularly characteristic
  phenotype_term:
    preferred_term: Fasciculations
    term:
      id: HP:0002380
      label: Fasciculations
- name: Respiratory Failure
  category: Respiratory
  frequency: VERY_FREQUENT
  notes: Leading cause of death in SMA types 1 and 2
  phenotype_term:
    preferred_term: Respiratory Failure
    term:
      id: HP:0002878
      label: Respiratory failure
  evidence:
  - reference: PMID:29091570
    supports: SUPPORT
    snippet: &#34;the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005).&#34;
    explanation: ENDEAR trial uses permanent assisted ventilation as a primary endpoint, confirming respiratory failure as a key clinical outcome in infantile SMA.
- name: Scoliosis
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  notes: Progressive spinal curvature due to paraspinal muscle weakness
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:16364894
    supports: SUPPORT
    snippet: &#34;The disease results in motor neuron loss and skeletal muscle atrophy.&#34;
    explanation: Progressive muscle weakness including paraspinal muscles leads to scoliosis in SMA patients.
biochemical:
- name: Creatine Kinase
  presence: Normal or mildly elevated
  context: Unlike muscular dystrophies, CK is typically normal or only mildly elevated
genetic:
- name: SMN1
  association: Causative
  notes: Autosomal recessive, homozygous deletion in 95% of cases, compound heterozygotes in remainder
  evidence:
  - reference: PMID:18572081
    supports: SUPPORT
    snippet: &#34;It is caused by homozygous disruption of the survival motor neuron 1 (SMN1) gene by deletion, conversion, or mutation.&#34;
    explanation: Lancet review confirms SMN1 gene disruption is the causative mechanism of SMA.
- name: SMN2
  association: Modifier
  notes: Copy number inversely correlates with severity; more copies = milder phenotype
treatments:
- name: Nusinersen (Spinraza)
  description: Antisense oligonucleotide modifying SMN2 splicing to increase functional SMN protein, intrathecal administration.
  evidence:
  - reference: PMID:29091570
    supports: SUPPORT
    snippet: &#34;Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group.&#34;
    explanation: ENDEAR trial demonstrates nusinersen improves survival and motor function in infantile SMA.
  - reference: PMID:29091570
    supports: SUPPORT
    snippet: &#34;Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein.&#34;
    explanation: NEJM paper confirms mechanism of action of nusinersen.
- name: Onasemnogene abeparvovec (Zolgensma)
  description: AAV9-based gene therapy delivering functional SMN1 gene, single IV infusion.
  evidence:
  - reference: PMID:35715567
    supports: SUPPORT
    snippet: &#34;Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.&#34;
    explanation: SPR1NT trial demonstrates gene therapy is effective in presymptomatic SMA infants.
- name: Risdiplam (Evrysdi)
  description: Oral small molecule SMN2 splicing modifier, daily oral administration.
  evidence:
  - reference: PMID:34320287
    supports: SUPPORT
    snippet: &#34;In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed improvements in motor function than the percentages observed in historical cohorts.&#34;
    explanation: FIREFISH trial demonstrates risdiplam improves motor function in infants with type 1 SMA.
- name: Supportive Care
  description: Respiratory support, nutritional management, physical therapy, orthopedic interventions.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Spinal_Muscular_Atrophy.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>